Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins
Interventions
DRUGinsulin detemir
Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes * Current treatment with insulin NPH or glargine * The selection of the subjects will be at the discretion of the individual physician
Exclusion criteria
* Current treatment with insulin detemir * Previous enrolment in this study * Hypersensitivity to insulin detemir or to any of the excipients. * Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight effect | 12 months prior to and 12 months after detemir treatment. |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in FPG levels | 12 months prior and 12 months after detemir treatment |
| Improvement in HbA1c levels | 12 months prior and 12 months after detemir treatment |
Countries
Czechia
Outcome results
None listed